支气管动脉灌注化疗联合腔内高剂量率放疗治疗晚期中央型肺癌的研究  

Efficacy of bronchial artery infusion chemotherapy combined with HDR intraluminal brachytherapy in late stage central lung cancer

作　　者：王梅芳[1] 刘玉全[1] 刘为舜[1] 雷怀定[1] 罗国仕[1] 熊畅[1] 刘先军[1] 涂明利[1] 

机构地区：[1]郧阳医学院附属太和医院呼吸内科,湖北十堰442000

出　　处：《中国内镜杂志》2008年第11期1158-1161,共4页China Journal of Endoscopy

摘　　要：目的探讨支气管动脉灌注化疗联合腔内高剂量率放疗治疗晚期中央型肺癌的近期疗效、毒副反应及安全性。方法64例晚期肺癌患者分别接受全身静脉化疗联合腔内高剂量率放疗和支气管动脉灌注化疗联合腔内高剂量率放疗。化疗用药:非小细胞肺癌采用MVP方案、小细胞肺癌采用EP方案,化疗3周期,每次间隔3、4周。均于第1次化疗结束2周后通过支气管镜置入施源器、模拟定位机后用192铱后装治疗机行腔内局部高剂量率放疗3次,腔内治疗每周一次,每次6~8Gy,共4次;化疗疗程结束后评估近期疗效和毒副反应。结果支气管动脉灌注化疗组完全缓解率75.00%、总有效率为93.75%,较全身静脉化疗组的50.00%和68.75%明显增高;其1年生存率为81.25%,较全身静脉化疗组43.75%显著提高;症状改善及KPS评分显效率分别高达96.88%和87.50%,较全身静脉化疗组62.50%和50.00%显著提高。毒副作用:支气管动脉灌注化疗组白细胞下降18.75%,恶心、呕吐25.00%,便秘、腹泻1.25%,较全身化疗组62.50%、62.50%和25.00%明显减轻。差异均有显著性。结论支气管动脉灌注化疗联合经支气管镜腔内高剂量率放疗治疗晚期肺...【Objective】 To investigate the curative effects,side effects and safety of bronchial artery infusion chemotherapy (BAI) combined with HDR intraluminal brachytherapy for cases with central type of lung cancer in late stage. 【Methods】64 cases were received HDR endobronchial brachytherapy combined with BAI or systemic chemotherapy. Non-small cell lung cancer (NSCLC) chemotherapeutic agents were according to MVP schema, small cell lung cancer (SCLC) according to EP schema, 3~4 weeks as a cycle and 3 cycles as a...

关 键 词：支气管动脉灌注 腔内近距离发射治疗 全身化疗 肺肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]